Healthcare Professionals
Du har precis klickat på en länk som tar dig till en annan webbplats. Om du fortsätter kommer du att lämna denna webbplats och gå till en webbplats som drivs av någon annan.
Medtronic Sverige varken granskar eller kontrollerar innehållet på den andra webbplatsen och tar inget ansvar för eventuella affärstransaktioner som du utför där. Din användning av den andra webbplatsen är föremål för användarvillkoren och sekretesspolicyn på den webbplatsen.
Det är möjligt att vissa produkter på den andra platsen inte är godkända i Sverige.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Välkommen till vår information för hälso- och sjukvårdspersonal.
Här hittar du produktinformation och annan info framtagen för dig som arbetar inom vården.
Arbetar du inom ett vårdyrke?
Healthcare Professionals
Balance® Biosurface provides reduced platelet activation and adhesion and preserves platelet function with a non-heparin coating.
Overview
Balance® Biosurface† is a hydrophilic polymer coating without heparin for cardiopulmonary bypass circuit devices. This coating reduces platelet adhesion and activation and preserves platelet function.‡ Representing Medtronic’s commitment to perfusion solutions, Balance Biosurface expands options used by cardiovascular surgery teams for comprehensive strategies to achieve the best possible outcomes for their patients undergoing cardiopulmonary bypass.
View details -- Read about the various properties of Balance Biosurface
For more details, download our product brochure below.
Balance Biosurface product brochure (PDF, 3.6 MB).
†Balance® is a trademark of Medtronic, Inc.
Technology licensed under agreement from BioInteractions, Limited,
United Kingdom.
‡See graph below.
Comparison between Balance-coated and uncoated in vitro bench test circuits of percentage of platelets that are activated with adenosine diphosphate (ADP @ 20 µM) in circulating heparinized human blood over time. Balance Biosurface is associated with a greater percentage of functional platelets (‡ p < 0.02 at 10, 30, 60 and 120 minutes).
Warnings: A strict anticoagulation protocol should be followed and anticoagulation should be routinely monitored during all procedures. The benefits of extracorporeal support must be weighed against the risk of systematic anticoagulation and must be assessed by the prescribing physician.
Caution: Swedish law restricts devices coated with Cortiva™ BioActive Surface, Trillium Biosurface and Balance Biosurface to sale by or on the order of a physician. For a complete listing of indications, contraindications, precautions and warnings, please refer to the Instructions for Use which accompany each product.
Why Use?
Blood is naturally compatible with vascular endothelium, not artificial surfaces.
Blood recognizes the extracorporeal circuit surfaces as “foreign”, triggering coagulation and inflammatory events that may lead to adverse patient outcomes.
Responses to Blood-Material Contact
Biocompatible surfaces for Medtronic extracorporeal circulation technologies mimic critical characteristics of the vascular endothelium.
Warnings: A strict anticoagulation protocol should be followed and anticoagulation should be routinely monitored during all procedures. The benefits of extracorporeal support must be weighed against the risk of systematic anticoagulation and must be assessed by the prescribing physician.
Caution: Swedish law restricts devices coated with Cortiva™ BioActive Surface, Trillium Biosurface and Balance Biosurface to sale by or on the order of a physician. For a complete listing of indications, contraindications, precautions and warnings, please refer to the Instructions for Use which accompany each product.
Lamba NMK, Cooper SL. Interaction of blood with artificial surfaces. In: Coleman RW, Clowes AW, George JN, Hirsh J, Marder V, eds. Hemostasis and thrombosis: Basic principles and practice, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:661-672.
Edmunds LH, Stenach N. Blood-surface interface. In: Gravlee GP, Davis RF , Jurusz M, Utley JR, eds. Cardiopulmonary bypass: Principles and practice, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:149-166.
Coleman RW, Clowes AW, George JN, Hirsh J, Marder V. Overview of Hemostasis. In: Coleman RW, Clowes AW, George JN, Hirsh J, Marder V, eds. Hemostasis and thrombosis: Basic principles and practice, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:3-16.
Baier RE , Dutton RC . Initial events in interactions of blood with a foreign surface. J Biomed Mater Res. 1969;3(1):191-206.
Paparella D, Yau TM , Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg. 2002 ;21(2):232-244.
Okkema AZ, et al. Physical and blood contacting characteristics of propyl sulphonate grafted biomer. Biomaterials 1991;12:3-12.
Grasel TG, et al. Properties and biological interactions of polyurethane aniomers: effect of sulfonate incorporation. J Biomed Mater Res 1989;311-338.
Lelah MD, et al. Polyether-urethane ionomers: surface property/ex vivo blood compatibility relationships. J Colloid Interface Sci 1985;104:422-439.
Silver JH, et al. Anticoagulant effects of sulphonated polyurethanes. Biomaterials 1992;13:339-343.
Charef S, et al. Heparin-like functionalized polymer surfaces: discrimination between catalytic and adsorption processes during the course of thrombin inhibition. Biomaterials 1996;17:903-912.
Han DK, et al. Heparin-like anticoagulant activity of sulphonated poly(ethelene oxide) and sulphonated poly(ethylene oxide)-grafted polyurethane. Biomaterials 1995;16:467-471.
Santerre JP, et al. Effect of sulfonation of segmented polyurethanes on the transient adsorption of fibrinogen from plasma: possible correlation with anticoagulant behaviour. J Biomed Mater Res 1992;26:39-57.